JP Morgan Chase
SRPT icon

JP Morgan Chase’s Sarepta Therapeutics SRPT Stock Holding History

JP Morgan Chase’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-108,600
Closed -$2.34M – 7872
2025
Q4 		$2.34M Sell
108,600
-110,500
-50% -$2.33M ﹤0.01% 3964
2025
Q3 		$4.22M Buy
219,100
+112,800
+106% +$2.01M ﹤0.01% 3511
2025
Q2 		$1.82M Buy
106,300
+51,300
+93% +$2.19M ﹤0.01% 3984
2025
Q1 		$3.51M Sell
55,000
-42,500
-44% -$4.47M ﹤0.01% 3454
2024
Q4 		$11.9M Buy
97,500
+40,000
+70% +$4.9M ﹤0.01% 2533
2024
Q3 		$7.18M Buy
57,500
+57,300
+28,650% +$7.92M ﹤0.01% 2914
2024
Q2 		$31.6K Sell
200
-51,000
-100% -$6.55M ﹤0.01% 6025
2024
Q1 		$6.63M Sell
51,200
-581,800
-92% -$71.3M ﹤0.01% 2847
2023
Q4 		$61M Sell
633,000
-28,800
-4% -$2.76M 0.01% 1117
2023
Q3 		$80.2M Buy
661,800
+654,000
+8,385% +$73.9M 0.01% 898
2023
Q2 		$893K Sell
7,800
-366,300
-98% -$47.2M ﹤0.01% 4145
2023
Q1 		$51.6M Buy
374,100
+95,700
+34% +$12.4M 0.01% 1091
2022
Q4 		$36.1M Buy
278,400
+220,200
+378% +$25.5M ﹤0.01% 1274
2022
Q3 		$6.43M Buy
+58,200
New +$5.87M ﹤0.01% 2507
2022
Q2 		– Sell
-50,100
Closed -$3.91M – 6868
2022
Q1 		$3.91M Sell
50,100
-354,300
-88% -$27.1M ﹤0.01% 3212
2021
Q4 		$36.4M Buy
404,400
+204,400
+102% +$17.5M ﹤0.01% 1384
2021
Q3 		$18.5M Buy
+200,000
New +$15.4M ﹤0.01% 1832
2021
Q1 		– Sell
-30,000
Closed -$5.12M – 6337
2020
Q4 		$5.12M Buy
30,000
+17,500
+140% +$2.59M ﹤0.01% 2799
2020
Q3 		$1.77M Buy
+12,500
New +$1.9M ﹤0.01% 3317
2020
Q1 		– Sell
-144,100
Closed -$18.6M – 5700
2019
Q4 		$18.6M Buy
144,100
+69,400
+93% +$7M ﹤0.01% 1654
2019
Q3 		$5.63M Sell
74,700
-295,700
-80% -$34.9M ﹤0.01% 2607
2019
Q2 		$48.1M Buy
370,400
+151,700
+69% +$18.4M 0.01% 981
2019
Q1 		$26.1M Buy
218,700
+191,700
+710% +$24.6M 0.01% 1357
2018
Q4 		$2.95M Sell
27,000
-17,000
-39% -$2.13M ﹤0.01% 2984
2018
Q3 		$7.11M Sell
44,000
-1,000
-2% -$137K ﹤0.01% 2476
2018
Q2 		$5.95M Buy
+45,000
New +$4.24M ﹤0.01% 2543
2018
Q1 		– Sell
-85,000
Closed -$4.73M – 5616
2017
Q4 		$4.73M Buy
85,000
+16,500
+24% +$874K ﹤0.01% 2728
2017
Q3 		$3.23M Buy
+68,500
New +$2.74M ﹤0.01% 2878
2017
Q1 		– Sell
-20,000
Closed -$549K – 5218
2016
Q4 		$549K Buy
+20,000
New +$803K ﹤0.01% 3723
2015
Q1 		– Sell
-13,500
Closed -$195K – 4255
2014
Q4 		$195K Buy
+13,500
New +$229K ﹤0.01% 4032

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase's SRPT Position: Q1 2026 in Review

JP Morgan Chase reduced its Sarepta Therapeutics (SRPT) stake by 5.5% in Q1 2026, selling an estimated $790K and leaving 703,191 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

JP Morgan Chase first reported a position in SRPT in Q2 2013 and has held it in 44 quarters since. The position peaked at $559M in Q3 2023. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • JP Morgan Chase held 703,191 shares of Sarepta Therapeutics worth $14.4M as of Q1 2026.
  • JP Morgan Chase sold 40,797 Sarepta Therapeutics shares in Q1 2026, an estimated $790K.
  • Sarepta Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2363 holding.
  • JP Morgan Chase first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 44 quarters since.
  • JP Morgan Chase's Sarepta Therapeutics position peaked at $559M in Q3 2023.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.